SLC5A2 and fibrosis: Furthermore, there is increasing evidence that SGLT2 inhibition directly inhibits pro‐inflammatory pathways responsible for cardiac fibrosis and adverse cardiac remodelling in HF and indeed this is borne out in several cardiac MRI studies.28, 32